Sakai, Japan

Buichi Fujitani


Average Co-Inventor Count = 6.6

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1990-2005

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Buichi Fujitani: Innovator in Pharmaceutical Chemistry

Introduction

Buichi Fujitani is a notable inventor based in Sakai, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on various chemical compounds. With a total of 4 patents to his name, Fujitani has established himself as a key figure in the development of new therapeutic agents.

Latest Patents

Fujitani's latest patents include groundbreaking work on pyrrolidine derivatives, which serve as chymase inhibitors. These novel compounds are designed to be useful as intermediates for the synthesis of active pharmaceutical ingredients. The formula for these pyrrolidine derivatives includes various substituents such as cycloalkyl, substituted or unsubstituted phenyl, and other complex groups. Additionally, he has worked on Prostaglandin I2 derivatives, further showcasing his expertise in medicinal chemistry.

Career Highlights

Throughout his career, Fujitani has been associated with prominent companies in the pharmaceutical and chemical industries. He has worked with Dainippon Pharmaceutical Company, Limited and Asahi Glass Company, Limited, where he contributed to various research and development projects. His work has had a lasting impact on the field, leading to advancements in drug development.

Collaborations

Fujitani has collaborated with esteemed colleagues such as Tomoyuki Asai and Arata Yasuda. These partnerships have fostered a collaborative environment that has enhanced the innovation process and led to the successful development of new chemical entities.

Conclusion

In summary, Buichi Fujitani is a distinguished inventor whose work in pharmaceutical chemistry has resulted in valuable patents and collaborations. His contributions continue to influence the development of new therapeutic agents, making him a significant figure in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…